ROSEMARIE ZOROLA: Open Payments
NPI 1255961942 · DUDLEY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,670 in 73 payments from 10 companies in 2025. Trend: 2023 $2,143 · 2024 $1,837 · 2025 $1,670
Food & beverage: $1,549Education: $121
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $369 |
| ABBVIE INC. | 15 | $347 |
| Janssen Pharmaceuticals, Inc | 7 | $232 |
| Vanda Pharmaceuticals Inc. | 14 | $168 |
| Otsuka America Pharmaceutical, Inc. | 11 | $144 |
| Alkermes, Inc. | 4 | $143 |
| Teva Pharmaceuticals USA, Inc. | 9 | $137 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Lundbeck LLC | 2 | $45 |
| Lilly USA, LLC | 1 | $33 |
Products named: CAPLYTA, VRAYLAR, FANAPT, REXULTI, SPRAVATO, INVEGA SUSTENNA, AUSTEDO XR, LYBALVI.
Industry payments across MA — which companies pay providers there.
